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Introduction {#sec001}
============

We and others have reported that hearts of neonatal pigs are able to regenerate myocardial tissue lost to an acute myocardial infarction (MI) that occurs within the first two days following birth (postnatal day \[P\] 1) \[[@pone.0232963.ref001], [@pone.0232963.ref002]\]. On P28, measurements of left-ventricular (LV) anterior wall thickness reached 90% of measurements of those in age matched control animals and were accompanied by an increase in the expression of markers for cell-cycle activitiy and proliferation (Ki67, PH3, and Aurora B) compared again to age matched control animals. Furthermore, the correlation between regenerative capacity and cell-cycle marker expression suggests that myocardial regeneration in very young animals likely occurs by means of proliferation of endogenous cardiomyocytes. Consequentlyupstream regulators of cell-cycle activity may be effective therapeutic targets for promoting myocardial proliferation in older mammals \[[@pone.0232963.ref003], [@pone.0232963.ref004]\]. Most experimental strategies for enhancing myocardial recovery through modulating signaling pathways have focused on a single gene, growth factor, or other biologically active molecule \[[@pone.0232963.ref005], [@pone.0232963.ref006]\], and a number of studies have targeted the upstream regulators of major signaling cascades such as p38/MAP kinase \[[@pone.0232963.ref007]\], the Ras family of GTPases \[[@pone.0232963.ref008]\], or the transcription factors TBX5 \[[@pone.0232963.ref009]\] and GATA4/6 \[[@pone.0232963.ref010], [@pone.0232963.ref011]\] in older large animals. However, there have been few studies examining the cardiomyocyte proliferative window in large young mammals that correlate gene expression to corresponding protein levels and is coupled with in-vivo analysis \[[@pone.0232963.ref012]\].

The emerging field of bioinformatics provides new tools that can help scientists identify the regulatory steps influencing myocardial cell cycle and other biological processes. The analysis is performed in two steps. First, sequencing data generated from the experimental and control groups are compared to produce a list of differentially expressed genes (DEG) \[[@pone.0232963.ref013], [@pone.0232963.ref014]\]; then, pattern-matching algorithms \[[@pone.0232963.ref015], [@pone.0232963.ref016]\] compare the DEG list to databases of known pathways to determine which pathways are most consistent with the observed variations in gene expression. This approach has been widely used in computer simulations of cardiac regeneration; however, the databases typically comprise an aggregate of results from experiments performed in different cell and tissue types. As such, the results may not be accurate for a specific tissue of interest (e.g., myocardium). Because such analysis provides only a ranked list of pathways, it cannot be used to identify which components within the pathways may be targeted to validate the predicted outcome in-vivo or to produce a therapeutic effect \[[@pone.0232963.ref017]\].

For this report, we conducted the two steps of typical pathway analysis in reverse. First, we queried the KEGG Pathway Database to identify signaling cascades known to regulate cell-cycle and cell-fate determination \[[@pone.0232963.ref017]\]; and then used the results from our gene expression analyses \[[@pone.0232963.ref018]\] of pig heart samples undergoing MI at P1 and their age-matched normal from our previous study \[[@pone.0232963.ref019]\], to show that that five of the twenty putative cell-cycle/cell-fate pathways were up-regulated for 4 weeks in response to MI injury at P1. Collectively, our observations provide a comprehensive list of molecular targets for future in-vitro and in-vivo studies of myocardial regeneration.

Methods {#sec002}
=======

Animals {#sec003}
-------

All experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Alabama Birmingham (UAB) and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication No. 85--23). Pigs (Prestage Farms, Inc, West Point, MS) were fed every 4 hours with bovine colostrum on P1-P2, with a 1:1 ratio of colostrum:sow's milk on P3, and with cow's milk from P4 until sample collection. Supplemental iron was provided on P7, and the animals were housed in an incubator at \~85°F with room air until either P7 or P28 days of age. Surgical procedures are detailed in our previous report \[[@pone.0232963.ref019]\]; briefly, MI was induced via permanent ligation of the left descending coronary artery. Seven and 28 day old normal animals were used as controls.

RNA sequencing {#sec004}
--------------

RNA sequencing was performed according to the Illumina NGS protocol \[[@pone.0232963.ref020]\]. RNA was isolated from tissue samples (\~30 mg) collected from the border zone of ischemia in the hearts of MI animals and from the corresponding region of hearts in age-matched normal animals. Libraries were quantified via qPCR with equal amounts of RNA for all samples, and RNA concentrations were diluted to 3 nM before loading equimolar amounts onto the flow cells.

Sequencing data were processed in the Cheaha computer cluster at UAB (<https://docs.uabgrid.uab.edu/wiki/cheaha>). Paired-end fastq files were evaluated with the trim-galore \[[@pone.0232963.ref020]\] package for quality assessments of the input sequencing files, and mapping was conducted with the Ensembl pig genome assembly (Sscrofa11.1) \[[@pone.0232963.ref021]\] and STAR package v2.5.2 \[[@pone.0232963.ref022]\] to produce the sorted BAM (Binary Alignment Map) file format; following this step, the sorted BAM file was converted into the SAM (Sequence Alignment Map) format with SAMtools \[[@pone.0232963.ref023]\], and mapped transcripts (raw expression) were counted with the HTSeq/0.6.1 package \[[@pone.0232963.ref024]\]. Expression levels were normalized and differential gene expressions (DEG) (log~2~ of the fold-change and p-value) were analyzed with Deseq2 software \[[@pone.0232963.ref025]\]. In 3x3 comparsions, the probability of observing as extreme and more than 'all A-samples strictly greater than (or less than) B-samples' would be 0.5^9^ = 0.002. This is the p-value for the statistical result above. The p-values other cases are computed as in \[[@pone.0232963.ref023]\].

Pathway analysis {#sec005}
----------------

Focusing on cell cycle regulators, we used DEG results from MI and age-matched control heart samples to annotate the following KEGG\[[@pone.0232963.ref026]\] swine pathways:

1.  MAPK signaling pathway: The MAPK signaling pathway participates in many cellular functions, including cell proliferation, differentiation, and migration \[[@pone.0232963.ref027]\]. This pathway is critical in bridging from growth factor signaling to cell cycle intiation in mammalian cells \[[@pone.0232963.ref028]\].

2.  HIPPO signaling pathway: In this pathway, LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ and leads to apoptosis at high cell density \[[@pone.0232963.ref029]\]. Previous studies show that a deficiency of HIPPO signaling pathway is able to reverse systolic heart failure following myocardial infarction \[[@pone.0232963.ref030]\].

3.  RAS signaling pathway: This pathway functions as molecular switches in regulating cell proliferation, survival, growth, migration, differentiation and cytoskeletal dynamics \[[@pone.0232963.ref031]\].

4.  VEGF signaling pathway: VEGF activates Protein Kinase C gene expression \[[@pone.0232963.ref032]\]; PKC enters the RAS signaling pathway. There has been evidence showing the correlation between VEGF expression and reduce cardiomyocyte apoptosis \[[@pone.0232963.ref033]\].

5.  WNT signaling pathway: Wnt genes and their receptors stabilize beta-catenin. Beta-catenin activates cell-cycle transcription factors, such as LEF1 and MYC \[[@pone.0232963.ref034]\]. The HIPPO pathway could inhibit WNT signaling pathway and restrain cardiomyocyte proliferation \[[@pone.0232963.ref035]\].

6.  RAP1 signaling pathway: This pathway controls the cell division process \[[@pone.0232963.ref036]\].

7.  Hedgehog signaling pathway. This pathway regulates differentiation, proliferation, tissue polarity, stem cell population and carcinogenesis \[[@pone.0232963.ref037]\].

8.  JAK-STAT signaling pathway: The JAK/STAT pathway is the principal signaling mechanism for many cytokines and growth factors \[[@pone.0232963.ref038]\].

9.  cAMP signaling pathway: cAMP acts directly on protein kinase A and Epac genes \[[@pone.0232963.ref039], [@pone.0232963.ref040]\]. These genes activate the RAP1 and MAPK pathways, which regulates calcium homeostasis, muscle contraction, cell fate, and gene transcription \[[@pone.0232963.ref041]\].

10. ERBB signaling pathway: ERBB genes bind extracellular growth factor ligands to the MAPK signaling pathway \[[@pone.0232963.ref042]\], which regulates proliferation and differentiation.

11. cGMP-PGK signaling pathway \[[@pone.0232963.ref043], [@pone.0232963.ref044]\]: In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel\'s Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses.

12. Apelin signaling pathway: This pathway regulates angiogenesis, cardiovascular functions, cell proliferation \[[@pone.0232963.ref045], [@pone.0232963.ref046]\].

13. NF-kappa B signaling pathway: This pathway controls transcription of DNA, cytokine production and cell survival \[[@pone.0232963.ref047]\]

14. TNF signaling pathway: This pathway regulates the immune cells, which are recruited as response to injury. The pathway could induce apoptosis \[[@pone.0232963.ref048]\].

15. HIF-1 signaling pathway: implicated in proliferation of fetal cardiomyocytes \[[@pone.0232963.ref049]\].

16. FoxO signaling pathway. FoxO signaling pathway includes forkhead-box transcription factors regulating cell-cycle control \[[@pone.0232963.ref050]\].

17. Sphingolipid signaling pathway: implicated in satellite muscle cell cell-cycle initiation \[[@pone.0232963.ref051]\].

18. Phospholipase D signaling pathway. Phospolipase D signaling pathway regulates the production of the lipid second messenger phosphatidic acid. Posphatidic acid is involved in many biological processes, including cell-cycle activity \[[@pone.0232963.ref052]\].

19. mTOR signaling pathway. mTOR signaling pathway serves as a central regulator of cell metabolism, growth, proliferation and survival \[[@pone.0232963.ref053]\].

20. AMPK signaling pathway. AMPK signaling pathway regulates ATP production and consumption; therefore, it has a critical role in regulating growth \[[@pone.0232963.ref054]\].

For each gene in the above pathways, we determined which genes met the following criteria:

i.  Pro-proliferative and cell-cycle genes expressed at a significantly higher level in MI samples at P7 compared to controls. Average expression in MI-P7 samples are *at least two-fold higher* than CTL-P7 samples. MI-P7 error bars were required to be *strictly higher* than CTL-P7 error bars.

ii. Of genes which met criteria in i.), also had at least *two-fold* differential expression when comparing MI vs CTL at the sample collection day P28

### Western blotting {#sec006}

Tissues were lysed in Mammalian Protein Extraction Reagent (Fisher scientific, PI78501) with protease (Sigma, 04693116001) and phosphatase (Sigma, P0044) inhibitors; then, the lysates were denatured at 100°C for 6 min, separated in a 4--20% precast gel (Bio-rad, 4568093), and transferred onto a PVDF membrane (Bio-rad, 1704156). The membrane was incubated with 5% non-fat milk (Bio-rad, 1706404) for 30 min, with primary antibodies at 4°C overnight, and then with horseradish-peroxidase (HRP)--conjugated secondary antibodies for 30 min. Protein bands were detected with the chemiluminescent HRP substrate (Millipore, WBKLS0500) in a ChemiDocTM Imaging System (Bio-rad). Phosphorylated proteins were detected first; then, the blots were treated with stripping buffer (Fisher scientific, PI21059) before total protein expression was evaluated.

Results {#sec007}
=======

Pigs underwent induction of MI one day after birth (MI-P1), and gene-expression levels of pathway components in border-zone infarcted heart samples were compared to corresponding regions from hearts of age-matched controls, at P1, P7, and P28, via bulk RNA sequencing. Early and late postnatal genes were defined as those found to be upregulated in MI-P1 animals at P7 and P28, respectively. A minimum of 200 transcripts (raw count) was required for each gene from all samples, and upregulation was defined as an expression level that was at least two-fold greater in MI tissues compared to age-matched control tissues. For early-postnatal genes, upregulation was also required to have no increase in expression from P1 to P7 in control samples, alongside no overlap between error bars in P7-MI and P-7 controls. Of the 11 general signaling pathways that were associated with the cell cycle and cell fate in the KEGG Pathway Analysis database, five were comprehensively upregulated, from initial signaling molecule (e.g., growth factors and receptors) to final effector molecules (e.g., transcription factors and proliferative genes) at P7 and/or P28. The results for these five fully upregulated pathways are described in more detail below.

Mitogen-Activated Protein Kinase (MAPK) {#sec008}
---------------------------------------

MAPK signaling participates in many cellular functions, including proliferation, differentiation, and migration \[[@pone.0232963.ref027]\], and serves as a crucial link between extracellular growth factors and the regulation of cell cycle proteins in mammalian cells \[[@pone.0232963.ref028]\]. Three subpathways of MAPK signaling **(**[Fig 1](#pone.0232963.g001){ref-type="fig"}**)**, were comprehensively upregulated in hearts of MI-P1 pigs---1.) the canonical MAPK pathway, shown previously to contribute to myocardial regeneration \[[@pone.0232963.ref055]\] and initiating through activation of the CSF1-CSF1R axis \[[@pone.0232963.ref056]\], GRB2, SOS1/2, Ras family members KRAS/NRAS, ARAF/RAF1, MAP2K1/2 \[[@pone.0232963.ref057]\], MAPK1/3 \[[@pone.0232963.ref058]\], ATF4/ELK4/MYC \[[@pone.0232963.ref059]\], and SRF/FOS \[[@pone.0232963.ref006]\]; 2) a second CSF1-intiated pathway that followed the classic MAPK pathway through Ras-family activation before diverging to upregulate MAP3K1 \[[@pone.0232963.ref060]\], MAP2K4, MAPK8/9/10, FOS, and JUND \[[@pone.0232963.ref061]\]; and 3) a pathway that was initiated by CD14 and proceeds through upregulation of TAB1/2, MAP3K7 \[[@pone.0232963.ref062]\], IKBKG \[[@pone.0232963.ref063]\], NFKB1/2, and RELA/RELB \[[@pone.0232963.ref064]\]. Both the initial (CSF1, CSF1R, CD14) and terminal (ATF4, FOS, JUND, NFKB1/2, RELA/RELB) components of all three MAPK subpathways continued to be more highly expressed in MI-P1 than in age-matched control samples at P28, suggesting that MI-induced MAPK activation and myocardial regeneration persists for at least 4 weeks after myocardial injury; however, most (but not all) intermediate pathway components were upregulated only during the early-postnatal period (e.g. \_\_\_\_\_\_\_\_\_). NF1 and members of the DUSP gene family were also identified among the upregulated early postnatal genes, and function as MAPK inhibitors, suggesting MAPK-mediated myocardial regeneration may be promoted via NF1 and/or DUSP inhibition. Notably, the selective inhibition of DUSP genes has been shown to promote cardiac development \[[@pone.0232963.ref065]\], while deletion of NF1 in neonatal mice leads to cardiac hypertrophy and premature mortality \[[@pone.0232963.ref066]\].

![MAPK signaling is fully upregulated by MI injury in the hearts of 1-day-old pigs.\
(A) The subpathways of MAPK signaling are displayed in a flow chart; genes that were expressed at significantly higher levels in the hearts of MI-P1 animals than in Age-matched normal -P1 hearts at P7 (i.e., early postnatal genes) or P28 (i.e., late postnatal genes) are displayed in a red box or in red text, respectively. (B) The expression of the initial signaling molecules (CSF1/CSF1R, CD14, TGFB) and the terminal effector molecules (JUND, ATF4, FOS, NFKB2 and RELB) of the MAPK signaling pathway was evaluated at the indicted time points in MI-P1 and Age-matched normal -P1 (CTL) hearts.](pone.0232963.g001){#pone.0232963.g001}

Hippo {#sec009}
-----

The Hippo signaling pathway is controlled by the upstream regulator [Moesin](https://en.wikipedia.org/wiki/Moesin)-[Ezrin](https://en.wikipedia.org/wiki/Ezrin)-[Radixin](https://en.wikipedia.org/wiki/Radixin)-Like Protein (MERLIN, encoded by the NF2 gene), and proceeds through Salvador-1 (encoded by SAV1) to activate the LATS1/2-mediated phosphorylation of two transcription factors---YAP and WWTR1. Phosphorylated YAP/WWTR1 is sequestered in the cytoplasm where it is targeted for degradation, a process which has been shown to promote apoptosis in cultures of confluent cells \[[@pone.0232963.ref029]\]; however, when Hippo signaling is inhibited, unphosphorylated YAP/WWTR1 translocates into the nucleus, where it promotes the expression of genes that impede apoptosis and promote proliferation. The Hippo pathway may also suppress cardiomyocyte proliferation via the inhibition of Wnt signaling \[[@pone.0232963.ref035]\], and previous reports indicate that the inhibition of Hippo signaling may reverse the progression of heart failure in mice \[[@pone.0232963.ref030]\], while SAV1 and LATS1/2 inhibition can improve myocardial recovery \[[@pone.0232963.ref012]\]. Our analyses indicate that Hippo pathway components from NF2 through LATS1/2 were upregulated in MI-P1 pigs during the early postnatal period ([Fig 2](#pone.0232963.g002){ref-type="fig"}); however, the expression of YAP1/WWTR1 in MI-P1 and their age-matched controls were similar at Day 7 and Day 28, suggesting that the increase in LATS1/2 expression did not impede Hippo signaling via YAP1/WWTR1 degradation. Furthermore, the TGFB-SMAD subpathway of Hippo signaling was fully upregulated in MI-P1 pigs during the early postnatal period, culminating with increases in expression of the proliferative genes FGF1 \[[@pone.0232963.ref067]\] and ITGB2, and both the initial (TGFB) and terminal (ITGB2) components of the TGFB-SMAD subpathway remained upregulated in MI-P1 pigs on Day 28. Thus, any potential increase in LATS1/2-induced YAP1/WWTR1 phosphorylation and sequestration could have been offset by an increase in TGFB subpathway activity, particularly at later timepoints \[[@pone.0232963.ref068], [@pone.0232963.ref069]\].

![Hippo signaling is fully upregulated by MI injury in the hearts of 1-day-old pigs.\
(A) The subpathways of Hippo signaling are displayed in a flow chart; genes that were expressed at significantly higher levels in the hearts of MI-P1 animals than in Age-matched normal -P1 hearts at P7 (i.e., early postnatal genes) or P28 (i.e., late postnatal genes) are displayed in a red box or in red text, respectively. (B) The expression of an initial signaling molecule (TGFB1) and a terminal effector molecule (ITGB2) of the Hippo signaling pathway was evaluated at the indicted time points in MI-P1 and Age-matched normal -P1 (CTL) hearts.](pone.0232963.g002){#pone.0232963.g002}

Cyclic AMP (cAMP) {#sec010}
-----------------

cAMP levels increase in response to binding between G-protein coupled receptors (GPCRs) and their extracellular signaling ligands, and the resulting cAMP signaling cascade activates, notably, protein kinase A (PKA) via adenylyl cyclase, among several other kinases \[[@pone.0232963.ref039], [@pone.0232963.ref040]\], to activate RAP1 and MAPK pathways that regulate calcium homeostasis, muscle contraction, cell fate, and gene transcription \[[@pone.0232963.ref041]\]. A single initiating ligand, atrial natriuretic peptide (encoded by NPPA) \[[@pone.0232963.ref070]\], and its corresponding GPCR receptor, ADYCYAPR1R1, were upregulated in MI-P1 swine at Day 7, which led to upregulation of GNAS and ADYC5/6 **(**[Fig 3](#pone.0232963.g003){ref-type="fig"}**)**. ADYC5/6 subsequently activated the classic MAPK subpathway (MAP2K1/2, MAPK1/3, JUN, and FOS) via both the upregulation of PRKCA/B/C and sequential upregulation of RAPGEF3/4 and RAP1A/B. Activation of RAP1A/B (Ras protein) expression also resulted in afadin (AFDN gene) upregulation, which promotes actin cytoskeleton rearrangement and effects cell-cell adhesion, 2) the VAV2-RAC1-PAK1 subpathway, which also functions in cytoskeletal remodeling, and 3) PI3K-AKT1/2/3, which stimulates proliferation. Notably, the PRKCA/B/C subpathway also proceeds through the PPP1C family of CREB inhibitors \[[@pone.0232963.ref071]\] which promote cell proliferation, and PPP1CA/B/C were all upregulated at Day 7, while CREB proteins were downregulated on Day 28, in MI-P1 pigs.

![cAMP signaling is altered by MI injury in the hearts of 1-day-old pigs.\
Two subpathways of cAMP signaling are displayed as flow charts. Genes that were expressed at significantly higher levels in the hearts of MI-P1 animals than in Age-matched normal -P1 hearts at P7 (i.e., early postnatal genes) or P28 (i.e., late postnatal genes) are displayed in a red box or in red text, respectively, and genes that were expressed at lower levels in MI-P1 than in Age-matched normal -P1 hearts at P28 are displayed in blue text.](pone.0232963.g003){#pone.0232963.g003}

Janus Kinase/Signal Transducers and Activators of Transcription (JAK-STAT) {#sec011}
--------------------------------------------------------------------------

The JAK/STAT pathway is the principal signaling mechanism for many cytokines and growth factors \[[@pone.0232963.ref038]\], and previous experiments have shown that early activation of JAK1/STAT3 is required for the proliferative response to cardiac injury in zebrafish \[[@pone.0232963.ref072]\]. Four JAK-STAT subpathways were fully upregulated in MI-P1 pigs ([Fig 4](#pone.0232963.g004){ref-type="fig"}), including the anti-apoptotic branch that proceeds through PIM1 \[[@pone.0232963.ref073]\], the MYC--CCND1/2/3 branch, which promotes cell-cycle progression \[[@pone.0232963.ref004], [@pone.0232963.ref074]\], the branch composed of PTPN11/GRB, SOS1/2, HRAS, and RAF1, which regulates proliferation and differentiation, and the branch that proceeds through PI3K, AKT1/2/3 \[[@pone.0232963.ref020]\], and MTOR to promote the cell cycle and cell survival. The upregulation of PIM1, MYC, and CCND1/2/3 persisted through Day 28.

![JAK/STAT signaling is fully upregulated by MI injury in the hearts of 1-day-old pigs.\
(A) The subpathways of JAK/STAT signaling are displayed in a flow chart; genes that were expressed at significantly higher levels in the hearts of MI-P1 animals than in Age-matched normal -P1 hearts at P7 (i.e., early postnatal genes) or P28 (i.e., late postnatal genes) are displayed in a red box or in red text, respectively. (B) The expression of three terminal effector molecules (PIM1, MYC, and CCND3) of the JAK/STAT signaling pathway was evaluated at the indicted time points in MI-P1 and Age-matched normal -P1 (CTL) hearts.](pone.0232963.g004){#pone.0232963.g004}

RAS {#sec012}
---

RAS genes function as molecular switches during the regulation of cell proliferation, survival, growth, migration, and differentiation, as well as cytoskeletal dynamics \[[@pone.0232963.ref031]\]. Our analysis indicated that in addition to MAPK and JAK-STAT signaling, CSF1/CSF1R activation in MI-P1 pigs also fully upregulated subpathways of Ras signaling that progressed through AFDN to control the formation of intercellular junctions, and through PI3K, AKT1/2/3, IKBKG, and NFKB1/RELA to activate cell-cycle progression and promote cellular growth, migration, and survival ([Fig 5](#pone.0232963.g005){ref-type="fig"}).

![RAS signaling is fully upregulated by MI injury in the hearts of 1-day-old pigs.\
The subpathways of RAS signaling are displayed in a flow chart; genes that were expressed at significantly higher levels in the hearts of MI-P1 animals than in Age-matched normal -P1 hearts at P7 (i.e., early postnatal genes) or P28 (i.e., late postnatal genes) are displayed in a red box or in red text, respectively.](pone.0232963.g005){#pone.0232963.g005}

In order to validate the activation of these signaling pathways at protein level, Western blotting experiments were performed and the data are summarized in [Fig 6](#pone.0232963.g006){ref-type="fig"}. We have conducted Western blot analyses of the expression of MAPK1/3, which mediates MAPK signaling; Akt, which mediates the cell-cycle regulatory activity of the JAK/STAT, cAMP, and RAS pathways; and the Wnt regulators GSK 3α/β and β-catenin, which act on downstream factors of the Hippo pathway. The amount of activated (i.e., phosphorylated) 42/44-MAPK and Akt in MI P1 LAD ligation hearts at page P7 or P28 was significantly greater in MI hearts than in age matched normal ([Fig 6](#pone.0232963.g006){ref-type="fig"}); thus, MAPK, Wnt/β-catenin and Akt signaling were upregulated at protein level for at least 28 days after LAD ligation at P1.

![Western blotting. LAD ligation at P1 activates key cell proliferation signaling pathways and downstream components.\
The expression of β-catenin, phosphorylated (Pho-) GSK 3α/β, total GSK 3α/β, Pho-Akt, total Akt, Pho-p42/44 MAPK, and total p42/44 MAPK was evaluated via Western blot. GAPDH levels were also evaluated to confirm equal loading. **(A)** Representative Western blotting of hearts from each time point/group; **(B)** Compiled Wetern blotting data, n = 3 hearts each bar. T-test (2 tails) with Bonferroni correction. \*, p\<0.05 between P28-MI vs P28-NL; \#, p \< 0.05 vs P7-MI; †, p\<0.05 vs P7-NL. Total protein blots were the same original blots stripped and reprobed.](pone.0232963.g006){#pone.0232963.g006}

Discussion {#sec013}
==========

Mammalian cardiomyocytes undergo cell cycle arrest in the early post-natal period; however, we have shown that when MI occurs in the hearts of 1-day-old piglets, endogenous cardiomyocytes proliferate to regenerate the injured myocardium\[[@pone.0232963.ref019]\]. Here, we present the results that shows which signaling pathways are responsible for MI-induced cardiomyocyte cell-cycle activation and proliferation Data from this study show that 5 of 20 possible regulatory pathways are upregulated in this model of early myocardial infarction in a large animal.

In conventional pathway analysis \[[@pone.0232963.ref075]\], differences in gene expression between control and experimental groups are used to search a pathway database to determine which pathways may be up- or down-regulated in response to the experimental interventions overall. In our current investigation, the KEGG Pathway Database was queried first, to identify signaling cascades that are known to regulate the cell cycle, cell-fate determination, and proliferation; then, the results from differential gene expression analyses with tissues from the hearts of MI-P1 or age-matched normal animals \[[@pone.0232963.ref019]\] were used to identify which of the known pathways were activated when MI was surgically induced one day after birth There are two advantages to this strategy. First, by choosing pathways that we are interested in a priori, we can test whether or not they are up regulated using unbiased measures. Second, we learn what pathways are likely not involved, thus giving a fuller picture of the process we are studying.

Five pathways (MAPK, Hippo, cAMP, JAK/STAT, and Ras) were upregulated at all points from the initiating master regulators (e.g., CSF1/CSF1R, TGFB, and NPPA) to the terminal effector molecules (e.g., ATF4, FOS, RELA/B, ITGB2, CCND1/2/3, PIM1, RAF1, MTOR, NKF1B), Although several of the upregulated genes are known to contribute to myocardial recovery in zebrafish or mice \[[@pone.0232963.ref055], [@pone.0232963.ref059], [@pone.0232963.ref061], [@pone.0232963.ref064], [@pone.0232963.ref068]--[@pone.0232963.ref070]\], this study is among the first to establish their involvement in the regenerative response to cardiac injury in neonatal large mammals. We also classified the genes as early- or late-postnatal, depending on whether they were upregulated on P7 or P28, respectively, and several of the upregulated genes appeared to link two or more pathways. Notably, the expression of many genes that were upregulated on P7 declined to normal levels by P28, which suggests that they may be associated with early developmental processes that subside shortly after birth. Nevertheless, a number of genes (e.g., CSF1/CSF1R, MYC, JUN/JUND and ATF4) were upregulated at both time points, which suggested that at least some regenerative activity persisted in MI-P1 animals for up to 4 weeks after MI.

We have known that cardiac muscle regeneration can only occur in low vertebrate animals for some time. Recently, there are significant reports indicating that in small mammal (mouse) cardiomyocyte can regenerate \[[@pone.0232963.ref076], [@pone.0232963.ref077]\]. However, the myocyte proliferation capacity quickly lost before postnatal-day 7 \[[@pone.0232963.ref076], [@pone.0232963.ref077]\]. The observation of LV functional recovery in newborn humans by fixing the coronary perfusion immediately after birth \[[@pone.0232963.ref078]\], suggest that a significant level of cardiomyocyte proliferation can occur in large mammal during early neonatal age. We recently completed pilot studies examining the cardiac regenerative potential of neonatal hearts in large mammals \[[@pone.0232963.ref001], [@pone.0232963.ref002]\], and our results demonstrate that the neonatal porcine heart is capable of regenerating from MI for only the first 2 days of life. This regenerative capacity is mediated by the proliferation of pre-existing cardiomyocytes \[[@pone.0232963.ref002], [@pone.0232963.ref076], [@pone.0232963.ref079]\], and is lost before postnatal-day 7, when cardiomyocytes permanently exit the cell cycle. Using a pig model of MI at P1, the present study demonstrate a few signaling pathways that are associated with the, activation of key myocyte proliferation signaling pathways. Most importantly, as we begin to better understand the mechanisms that regulate the drastic early postnatal decline in cardiomyocyte proliferation, we may be able to manipulate these mechanisms to promote myocardial regeneration in adult, as well as pediatric, patients.

In conclusion, the studies presented here build upon the results from our previous report \[[@pone.0232963.ref019]\] by conducting pathway analysis to determine which signaling mechansims contribute to the regenerative capacity of newborn pig hearts. However, unlike conventional pathway analysis, we queried the KEGG Pathway Database first, to identify signaling cascades that are known to regulate the cell-cycle and proliferation, and then conducted differential gene expression analyses to confirm whether the identified pathways were upregulated in myocardial tissues from the hearts of pigs that underwent MI surgery one day after birth. Collectively, our findings demonstrate a comprehensive list of key regulators that controls cardiomyocyte exiting cell-cycle shortly after birth, which are significant informations for future in-vitro and in-vivo studies of myocardial regeneration in large mammals.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The mammal hearts have been thought to be a post-mitotic tissue for decades till recent studies demonstrated that neonatal rodent and porcine hearts can regenerate following injuries. However, the regenerative capacity of the hearts losses when the animal pass p7 after birth. Thus, to determine the cellular and molecular mechanisms of mammal neonatal heart regeneration is critical for regenerative medicine. In the current study, the authors performed RNA sequence analysis to determine the key signaling pathways that activate after myocardial infarction injury. They found that five signaling pathways (MAPK, Hippo, cAMP, JAK/STAT, and Ras) were upregulated following neonatal cardiac injury, indicates they might contribute to regenerative capacity of neonatal porcine hearts. In my personal opinion, the current study could open several new research directions for studying cardiac regeneration. Thus, it is an important study in this research field. I only have some minor comments:

1\. The authors should add statistical analysis results in their figures and method section.

2\. In the discussion section, the authors might want to add some comments on potential approaches to regulate these important pathways to enhance adult cardiac regeneration.

3\. The resolution of the figures need to be enhanced for publication.

Reviewer \#2: This is a clear and well-written manuscript. The introduction is relevant and

theory based. The methods are appropriate. There are only two issues associated with publication:

1\) what is the reason of selecting pig for experiment among other mammals?

2\) How would you explain the novelty of your work in compare with \"MicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in rats\" Biomed Pharmacother 2019 Mar;111:1467-1477?

Reviewer \#3: In this manuscript, Zhang et al. performed RNA-seq on the neonatal pigs after myocardial injury to identify key regulators promoting cell-cycle activity. However, this manuscript is limited to pathway analysis without further validation or mechanism studies. The detailed points are as follows:

1 All these five pathways shown in this manuscript should be examined further at least at protein level, such as IF or western blot.

2 The RNA-seq is perform in the heart tissue with mixture of difference cell types. The pathway identified by this approach is very likely not cardiomyocyte-specific. For example, the up-regulation of CSF and CSF1R could be from fibroblasts and monocytes respectively. Please make these five signalings more specific by using IF to probe the protein of interest.

3 The unit of y axis in Fig.1B, 2B and 4B are not clearly labelled.
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Reviewer \#1: No
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Reviewer \#3: No
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12 Mar 2020

Response to Reviewers

Manuscript \# PONE-D-19-33077

"Identifying the Key Regulators that Promote Cell-cycle Activity in the Hearts of Early Neonatal Pigs after Myocardial Injury"

By Eric Y Zhang et al

We appreciate the editor and reviewers' careful and constructive critique of our manuscript. A point-by-point response to their comments are provided as follows.

Reviewer \#1: The mammal hearts have been thought to be a post-mitotic tissue for decades till recent studies demonstrated that neonatal rodent and porcine hearts can regenerate following injuries. However, the regenerative capacity of the hearts losses when the animal pass p7 after birth. Thus, to determine the cellular and molecular mechanisms of mammal neonatal heart regeneration is critical for regenerative medicine. In the current study, the authors performed RNA sequence analysis to determine the key signaling pathways that activate after myocardial infarction injury. They found that five signaling pathways (MAPK, Hippo, cAMP, JAK/STAT, and Ras) were upregulated following neonatal cardiac injury, indicates they might contribute to regenerative capacity of neonatal porcine hearts. In my personal opinion, the current study could open several new research directions for studying cardiac regeneration. Thus, it is an important study in this research field. I only have some minor comments:

1\. The authors should add statistical analysis results in their figures and method section.

Response: Thank you. It is done accordingly in the revised manuscript on page 6 the 2nd paragraph of the revised manuscript as follows:

"Sequencing data were processed in the Cheaha computer cluster at UAB (<https://docs.uabgrid.uab.edu/wiki/cheaha>). Paired-end fastq files were evaluated with bthe trim-galore \[1\] package for quality assessments of the input sequencing files, and mapping was conducted with the Ensembl pig genome assembly (Sscrofa11.1) \[2\] and STAR package v2.5.2 \[3\] to produce the sorted BAM (Binary Alignment Map) file format; then, the sorted BAM file was converted into the SAM (Sequence Alignment Map) format with SAMtools \[4\], and mapped transcripts (raw expression) were counted with the HTSeq/0.6.1 package \[5\]. Expression levels were normalized and differential gene expressions (log2 of the fold-change and p-value) were analyzed with Deseq2 software \[6\]. In 3x3 comparsions, the probability of observing as extreme and more than 'all A-samples strictly greater than (or less than) B-samples' would be 0.59 = 0.002. This is the p-value for the statistical result above. The p-values other cases are computed as in \[51\]"

2\. In the discussion section, the authors might want to add some comments on potential approaches to regulate these important pathways to enhance adult cardiac regeneration.

Response: Thank you for this important point. The following paragraph has been added on page 9, the last paragraph to page 10 the end of first paragraph, of the revised manuscript:

"We have known that cardiac muscle regeneration can only occur in low vertebrate animals for osmetime. Recently, there are significant reports indicating that in small mammal (mouse) cardiomyocyte can regenerate \[9, 10\]. However, the myocyte proliferation capacity quickly lost before postnatal-day 7 \[9, 10\]. The observation of LV functional recovery in newborn humans by fixing the coronary perfusion immediately after the birth \[11\], suggest that a significant level of cardiomyocyte proliferation can occur in large mammal during early neonatal age. We recently completed a pilot study examining the cardiac regenerative potential of neonatal hearts in large mammals \[7, 8\], and our results demonstrate that the neonatal porcine heart is capable of regenerating from MI for only the first 2 days of life. This regenerative capacity is mediated by the proliferation of pre-existing cardiomyocytes \[7-9\], and is lost before postnatal-day 7, when cardiomyocytes permanently exit the cell cycle. Using a pig model of MI at P1, the present study demonstrate a few signaling pathways that are associated with the, activation of key myocyte proliferation signaling pathways. Most importantly, as we begin to better understand the mechanisms that regulate the drastic early postnatal decline in cardiomyocyte proliferation, we may be able to manipulate these mechanisms to promote myocardial regeneration in adult, as well as pediatric, patients."

3\. The resolution of the figures need to be enhanced for publication.

Response: Yes, we agree. The resolution of all the figures have been enhanced accordingly

 

Reviewer \#2: This is a clear and well-written manuscript. The introduction is relevant and theory based. The methods are appropriate. There are only two issues associated with publication:

1\) what is the reason of selecting pig for experiment among other mammals?

Response: Thank you for asking this important question. For a long time, we have known that cardiac muscle regeneration can only occur in low vertebrate animals. Recently, there are significant reports that small mammal (mouse) cardiomyocyte can regenerate \[9, 10\]. This regenerative capacity is mediated via the proliferation of pre-existing cardiomyocytes \[9, 10\]. However, the myocyte proliferation capacity quickly lost before postnatal-day 7 \[9, 10\]. The observation of LV functional recovery in newborn humans by fixing the coronary perfusion immediately after the birth \[11\], suggest that a significant level of cardiomyocyte proliferation can occur in large mammal during early neonatal age.

The following paragraph has been added on page 9, the last paragraph to page 10 the end of first paragraph, of the revised manuscript:

"We have known that cardiac muscle regeneration can only occur in low vertebrate animals for sometime. Recently, there are significant reports indicating that in small mammal (mouse) cardiomyocyte can regenerate \[9, 10\]. However, the myocyte proliferation capacity quickly lost before postnatal-day 7 \[9, 10\]. The observation of LV functional recovery in newborn humans by fixing the coronary perfusion immediately after the birth \[11\], suggest that a significant level of cardiomyocyte proliferation can occur in large mammal during early neonatal age. We recently completed a pilot study examining the cardiac regenerative potential of neonatal hearts in large mammals \[7, 8\], and our results demonstrate that the neonatal porcine heart is capable of regenerating from MI for only the first 2 days of life. This regenerative capacity is mediated by the proliferation of pre-existing cardiomyocytes \[7-9\], and is lost before postnatal-day 7, when cardiomyocytes permanently exit the cell cycle. Using a pig model of MI at P1, the present study demonstrate a few signaling pathways that are associated with the, activation of key myocyte proliferation signaling pathways. Most importantly, as we begin to better understand the mechanisms that regulate the drastic early postnatal decline in cardiomyocyte proliferation, we may be able to manipulate these mechanisms to promote myocardial regeneration in adult, as well as pediatric, patients."

2\) How would you explain the novelty of your work in compare with \"MicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in rats\" Biomed Pharmacother 2019 Mar;111:1467-1477?

Response: Using a large mammal model, the current study seeks to examine the mechanisms that regulate the drastic early postnatal decline in cardiomyocyte proliferation. And in future, we aim to manipulate these mechanisms to promote myocardial regeneration in adult. Using a mall mammal model, the aforementioned study seeks to examine the mechanisms of acute cardiotoxicity induced by triptolid, in terms of microRNA expression, targeting, release dynamics as early biomarkers.

 

Reviewer \#3: In this manuscript, Zhang et al. performed RNA-seq on the neonatal pigs after myocardial injury to identify key regulators promoting cell-cycle activity. However, this manuscript is limited to pathway analysis without further validation or mechanism studies.

The detailed points are as follows:

1 All these five pathways shown in this manuscript should be examined further at least at protein level, such as IF or western blot.

Response: We agree and have conducted Western blot analyses of the expression of MAPK1/3, which mediates MAPK signaling; Akt, which mediates the cell-cycle regulatory activity of the JAK/STAT, cAMP, and RAS pathways; and the Wnt regulators GSK 3α/β and β-catenin, which act on downstream factors of the Hippo pathway. The amount of activated (i.e., phosphorylated) 42/44-MAPK and Akt in MI P1 apex resection (AR) hearts at P7 and P28 was significantly greater in AR hearts than in age matched normal hearts at each time points; thus, MAPK, Wnt/β-catenin and Akt signaling were upregulated for at least 28 days after AR induction at P1.

This figure and following paragraph have been included on page 6, paragraph 3 , and Figure 6, of the revised manuscript.

Western blotting. Tissues were lysed in Mammalian Protein Extraction Reagent (Fisher scientific, PI78501) with protease (Sigma, 04693116001) and phosphatase (Sigma, P0044) inhibitors; then, the lysates were denatured at 100 °C for 6 min, separated in a 4-20% precast gel (Bio-rad, 4568093), and transferred onto a PVDF membrane (Bio-rad, 1704156). The membrane was incubated with 5% non-fat milk (Bio-rad, 1706404) for 30 min, with primary antibodies at 4 °C overnight, and then with horseradish-peroxidase (HRP)--conjugated secondary antibodies for 30 min. Protein bands were detected with the chemiluminescent HRP substrate (Millipore, WBKLS0500) in a ChemiDocTM Imaging System (Bio-rad). Phosphorylated proteins were detected first; then, the blots were treated with stripping buffer (Fisher scientific, PI21059) before total protein expression was evaluated.

2 The RNA-seq is perform in the heart tissue with mixture of difference cell types. The pathway identified by this approach is very likely not cardiomyocyte-specific. For example, the up-regulation of CSF and CSF1R could be from fibroblasts and monocytes respectively. Please make these five signaling more specific by using IF to probe the protein of interest.

Response: The present investigation

3 The unit of y axis in Fig.1B, 2B and 4B are not clearly labelled.

Response: Thank you . The unit of y axis in Fig.1B, 2B and 4B are clearly labelled in the revised manuscript.
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